Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New Formulation Adebrelimab (SHR-1316) in Advanced Tumors
NCT04979390Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 1, open-label, single-arm trial of adebrelimab in solid tumor, sponsored by Hengrui. Primary endpoints: Incidence and severity of adverse events/serious adverse events at 1 year, Maximum plasma concentration at 1 year and 8 more. Status: unknown.
02
Drugs
adebrelimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04979390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979390.